ID: ALA242724

Max Phase: Preclinical

Molecular Formula: C23H27N5O3S

Molecular Weight: 453.57

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc2nc(N3CCN(C(=O)c4cccs4)[C@H]4CCCC[C@H]43)nc(N)c2cc1OC

Standard InChI:  InChI=1S/C23H27N5O3S/c1-30-18-12-14-15(13-19(18)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)20-8-5-11-32-20/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26)/t16-,17+/m0/s1

Standard InChI Key:  UIAXVFLURTXSJC-DLBZAZTESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 453.57

Molecular Weight (Monoisotopic): 453.1835

AlogP: 3.56

#Rotatable Bonds: 4

Polar Surface Area: 93.81

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.21

CX LogP: 3.92

CX LogD: 3.71

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.65

Np Likeness Score: -1.05

References

1. Sagratini G, Angeli P, Buccioni M, Gulini U, Marucci G, Melchiorre C, Leonardi A, Poggesi E, Giardinà D..  (2007)  Synthesis and alpha(1)-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin.,  15  (6): [PMID:17276073] [10.1016/j.bmc.2007.01.028]

Source

Source(1):

• Scientific Literature